Prognostic factors in bone sarcomas

Acta Orthopaedica Scandinavica, Supplement

Volumn 68, Issue 273, 1997, Pages 156-160

  Saeter G ^a   Elomaa, I ^b   Wahlqvist, Y ^c   Alvegard T A ^d   Wiebe, T ^d   Monge, O ^e   Forrestier, E ^f   Solhem, O P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTOSTATIC AGENT; GLYCOPROTEIN P; METHOTREXATE; ANTINEOPLASTIC AGENT;

AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; EWING SARCOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OSTEOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR VOLUME; ADOLESCENT; ADULT; BONE TUMOR; CHILD; FEMALE; MALE; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SARCOMA;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; PROGNOSIS; SARCOMA; SEX FACTORS;

EID: 0031066103     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Taylor WF, Ivins JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 1985; 60: 91-104.
2. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial SloanKettering experience. J Clin Oncol 1992; 10: 5-15.
3. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-31.
4. Sæter G, Bruland ØS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol 1996; in press.
5. Picci P, Bacci G, Rosito P, et al. The importance of chemotherapy-induced necrosis as prognostic factor in localized Ewing's sarcoma (ES) of the extremities. Med Ped Oncol 1996; 27: 255.
6. Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991; 68: 733-7.
7. Bacci G, Picci P, Briccoli A, et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992; 78: 200-6.
8. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697-705.
9. Dunst J, Sauer R, Burgers JM, et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the cooperative Ewing's sarcoma studies CESS 81 and CESS 86. Cancer 1991; 67: 2818-25.
10. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14: 848-58.
11. Oberlin O, Zucker JM, Brunat-Mentigny M, et al. Prognostic factors in the treatment of localized Ewing's sarcoma. Ann Oncol 1992; 3 Suppl. 5: 169
12. Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21: 1501-8.
13. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients. Eur J Cancer [A] 1994; 30A: 620-6.
14. Terrier P, Henry-Amar M, Triche TJ, et al. Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis. Eur J Cancer [A] 1995; 31A: 307-14.
15. SæerG, Alvegård TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
16. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993; 11: 1763-9.
17. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European cooperative trial. Cancer 1988; 61: 23-32.
18. Bacci G, Figus E, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation (OEM): results in 23 patients treated with chemotherapy followed by simultaneous resection of primary and metastatic lesions (SRPSL). Proc 9th Meeting of European Musculoskeletal Oncology Society 1996; 53.
19. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Enal J Med 1995; 333: 1380-5.
20. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-37.
21. Souhami RL. Chemotherapy for osteosarcoma. Br J Cancer 1989; 59: 147-8.
22. Saeter G. Treatment of osteosarcoma with high-dose methotrexate-containing neoadjuvant chemotherapy. Scandinavian Sarcoma Group data. Med Ped Oncol 1996; 27: 263.
23. Triche TJ. Multiple-drug resistance in Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Am J Clin Pathol 1994; 102: 1-2.
24. Rocssncr A, Ueda Y, Bockhom Dworniczak B, et al. Prognostic implication of immunodetection of P glycoprotein in Ewins's sarcoma. J Cancer Res Clin Oncol 1993; 119: 185-9.
25. Ferrari S, Sassoli V, Orlandi M, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993; 5: 135-41.
26. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51.
27. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993; 71: 1224-30.
28. Dierick AM, Langlois M, Van Oostveldt P, Roels H. The prognostic significance of the DNA content in Ewing's sarcoma: A retrospective cytophotometric and flow cytometric study. Histopathology 1993; 23: 333-9.
29. Bruland OS, Fodstad O, Aas M, et al. Immunoscintigraphy of bone sarcomas - Results in 5 patients. Eur J Cancer [A] 1994; 30A: 1484-9.
30. Bruland ØS, Pihl A. Immunoscintigraphy and radioimmunotherapy. Useful approaches in the management of osteogenic sarcoma? in Novak J (ed): Frontiers of osteosarcoma research. Hogrefe and Huber, 1993, pp 149-159.
31. Haines DM, Bruland ØS, Matte G, et al. Immuno-scintigraphic detection of primary and metastatic canine osteosarcoma with F(ab')2 fragments of osteosarcoma-associated antibody TP-3. Anti-Cancer Res 1992; 12: 2151-8.
32. Marcus Jr RB, Graham-Pole J, Scarborough MT, et al. End-intensification with high-dose chemotherapy, total body irradiation, and autologous bone marrow transplant for high-risk localized Ewing's sarcoma. Med Fed Oncol 1996; 27: 238.
33. Toni A, Neff JR, Sudanese A, et al. The role of surgical therapy in patients with nonmetastatic Ewing's sarcoma of the limbs. Clin Orthop 1993; 225-40.
34. Sauer R, Jurgens H, Burgers JM, et al. Prognostic factors in the treatment of Ewing's sarcoma. Radiother Oncol 1987; 10: 101-10.
35. Dockhorn-Dwomiczak B, Schäfer K-L, Dantcheva R, et al. Prognostic features of Ewing's sarcoma on plain radiograph and computed tomography scan after initial treatment. Cancer 1994; 74: 988-9.
36. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.